Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial

Aimee L. McRae-Clark, Kathleen T. Brady, Karen J. Hartwell, Kathleen White, Rickey E. Carter

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.

Original languageEnglish (US)
Pages (from-to)539-544
Number of pages6
JournalJournal of Attention Disorders
Issue number7
StatePublished - Oct 2011


  • attention deficit hyperactivity disorder
  • stimulant misuse
  • transdermal methylphenidate

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Clinical Psychology


Dive into the research topics of 'Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial'. Together they form a unique fingerprint.

Cite this